#India #Mumbai #S&P Global #Corporate Sustainability #Piramal Pharma

Piramal Pharma Achieves Notable Score Increase

Piramal Pharma Limited (PPL) has made headlines by announcing a remarkable score of 63 on the 2025 S&P Global Corporate Sustainability Assessment (CSA). This impressive score not only represents a 15% increase from last year’s 55 but also places the company in the top 91st percentile of the pharmaceutical industry. The S&P Global CSA stands as one of the most respected benchmarks for sustainability evaluation across numerous sectors, reflecting a company's dedication to responsible environmental and social operations.

Located in Mumbai, India, PPL includes crucial divisions such as Piramal Pharma Solutions, a major global Contract Development and Manufacturing Organization (CDMO), and Piramal Critical Care, which focuses on hospital generics. The organization's success in the CSA underscores its ongoing commitment to sustainability by integrating Environmental, Social, and Governance (ESG) principles into every facet of its operations.

A Commitment to Sustainability

The evaluation process of the S&P Global CSA scrutinizes various sustainability practices, enabling companies to measure their efforts against their peers. Companies are assessed on their governance, maturity, environmental performance, and their ability to create long-term value. The increase in PPL's score illustrates not only their dedication to sustainability but also the effectiveness of the strategies they have deployed in recent years.

In particular, PPL has taken proactive measures to enhance its sustainability practices. A notable initiative includes the installation of a 240 kWp rooftop solar system in April 2024, aimed at bolstering the organization’s renewable energy sources. Throughout FY2025, this system generated approximately 607 gigajoules of renewable electricity, resulting in a decreased emission of 123 tons of CO₂ equivalent. Such steps are at the forefront of PPL's commitment to integrating clean energy options within its operational structure.

To facilitate their sustainability efforts, PPL employs a four-pillared approach comprising Business Resilience, Quality Excellence, Responsible Operations, and Stakeholder Centricity. By focusing on these areas, they not only aim at achieving business goals but also engage in practices that promote the health of their stakeholders and the planet as a whole.

CEO Peter DeYoung emphasized the importance of this accomplishment, stating, “Our progress on the S&P Global CSA underscores our unwavering dedication to responsible operations and sustainable growth.” He added that as the company continues to expand, they remain steadfast in their pursuit of excellence, focusing on contributing positively to global health and environmental goals.

Looking Ahead

With this recent recognition, PPL is positioned to further elevate its sustainability initiatives and continue fostering positive changes across its operations and partnerships. They recognize that such an enhanced score can instill greater confidence among global investors and clientele, thereby strengthening their market position.

Besides their remarkable sustainability performance, Piramal Pharma Limited is also committed to diversifying its product and service offerings across the globe. Their integrated development and manufacturing capabilities, which span 17 facilities, along with a distribution network that reaches over 100 countries, are testaments to their dedication to delivering optimal healthcare solutions.

In summary, the notable score increase on the S&P Global CSA not only reveals PPL's commitment to sustainability but also illustrates the growing trend among corporations striving to prioritize environmental and social responsibilities in today's business landscape. As they continue on this path, Piramal Pharma Limited stands as an exemplary model for other organizations aiming to integrate sustainability within their corporate strategy effectively.